Eff ect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
Introduction
For many women with early-stage breast cancer, breastconserving surgery can remove any macroscopic disease that has been detected; however, some microscopic tumour foci might remain in the conserved breast that could, if untreated, lead to locoregional recurrence or life-threat ening distant metastases, or both. This report up dates previous analyses from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) of individual patient data from the randomised trials of radiotherapy after breast-conserving surgery. [1] [2] [3] [4] [5] It includes further follow-up for nine of the ten trials analysed previously; 5 adds data from seven new trials, six of which were in low-risk women; and increases the total number of women analysed by nearly 50%. The report focuses mainly on women for whom pathological axillary lymph node status is known (negative [pN0] or positive [pN+] ), because such information is usually available nowadays. It assesses the extent to which the radiotherapy-related absolute reduction in 10-year risk of fi rst recurrence at any site (locoregional or distant) varies for women with diff erent prognostic and other factors. It then relates the absolute reduction in the 15-year risk of breast cancer death to the absolute reduction in the 10-year risk of a recurrence. www.thelancet.com Vol 378 November 12, 2011
Methods

Study design
Eligible trials were those beginning before the year 2000 of adjuvant radiotherapy versus no radiotherapy following breast-conserving surgery for invasive cancer. Trial identifi cation and data handling were as previously reported. 5 For every woman, information was sought regarding initial characteristics, allocated treatment, time to fi rst recurrence, whether the fi rst recurrence was locoregional or distant (excluding contra lateral breast cancer), and date last known alive or date and underlying cause of death. When no recurrence was reported before breast cancer death, distant recurrence was assumed to have just preceded it. If contralateral breast cancer occurred before any other recurrence, follow-up was censored on that date in recurrence analyses.
Statistical analysis
The method used in this study diff ers from that used previously. 5 First, to avoid assumptions about how locoregional and distant recurrence relate to each other, the main emphasis is on analyses of any fi rst recurrence rather than, as before, of time to locoregional recurrence as a fi rst event. Second, most analyses of recurrence present data for only 10 years, because many of these trials did not follow up women beyond this time for recurrence. This absence of follow-up should not bias the estimated proportional eff ect on recurrence after year 10, but could aff ect estimates of the absolute recurrence risk after year 10 substantially. Third, deaths of unknown cause before recurrence are no longer attributed to breast cancer, because most occurred many years after trial entry, by which time non-breast-cancer mortality predominated. Other aspects of the methods used are as before. 5 Log-rank analyses are stratifi ed by trial, individual follow-up year, and nodal status. They are also stratifi ed by age, either in fi ve groups (<40, 40-49, 50-59, 60-69, 70+ years) or, when data are also subdivided by other factors, in two groups (<50 and 50+ years).
Analyses of the dependence of absolute risk, and absolute risk reduction, on several factors simultaneously use Poisson regression fi tted by maximum likelihood (webappendix pp [20] [21] [22] [23] [24] [25] . In these analyses absolute risk of any fi rst recurrence is adjusted for trial, individual follow-up year, nodal status, and age (fi ve groups), and also for tumour grade, tumour size, oestrogen-receptor (ER) status, and whether or not tamoxifen had been used in both randomised groups in the trial.
Preliminary results were presented to collaborators in September, 2010. A report was circulated to collaborators for comment in January, 2011, and then revised centrally.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The Secretariat had full access to all data and analyses. Submission for publication was decided only by the writing committee.
Results
Information was available for 10 801 women in 17 trials (table 1) . Six trials were of radiotherapy after lumpectomy and included both low-risk and high-risk women 23·6  11·3  7·6  3·7  1·0  0·0   All women  17  1976-99 10 801  3143  9·5  109·1  49·8 34·1 17·2  6·3  1·7 *Only unconfounded trials are considered-ie, trials in which there was no diff erence between the treatment groups in the type or extent of surgery or in the use of systemic therapy. Two further eligible trials, 23, 24 both category A with a total of 133 women, were identifi ed but data were unavailable. Details of the 17 available trials are given in webappendix pp 4, 45-47. †Elsewhere, these trial categories are abbreviated to: (A) Lumpectomy: original; (B) >Lumpectomy; (C) Lumpectomy: low risk. In category A, 55% were pathologically node negative, 5% were aged 70+ years, 10% had low-grade tumours, 54% had T1 tumours (1-20 mm), 81% had oestrogen-receptor (ER)-positive disease or unknown status, and 44% were in trials in which tamoxifen was used in both trial groups. In category B, 81% were pathologically node negative, 10% were aged 70+ years, 9% had low-grade tumours, 89% had T1 tumours, 86% had ER positive disease or unknown status, and 6% were in trials in which tamoxifen was used in both trial groups. In category C, 73% were pathologically node negative, 40% were aged 70+ years, 33% had low-grade tumours, 90% had T1 tumours, 98% had ER positive disease or unknown status, and 88% were in trials in which tamoxifen was used in both trial groups. The 10-year risk of any (locoregional or distant) fi rst recurrence was 19·3% in women allocated to radiotherapy and 35·0% in women allocated to breast-conserving surgery only, corresponding to an absolute risk reduction of 15·7% (95% CI 13·7-17·7, 2p<0·00001; fi gure 1). Nearly three-quarters of fi rst recurrences in the no radiotherapy group were locoregional (25% locoregional fi rst, 10% distant fi rst), compared with fewer than half of those in the radiotherapy group (8% locoregional fi rst, 12% distant fi rst; webappendix p 9). In addition to reducing recurrence substantially, radiotherapy also reduced breast cancer death by a moderate amount: the 15-year absolute risk reduction was 3·8% (95% CI 1·6-6·0, 2p=0·00005), suggesting on average about one breast cancer death avoided for every four recurrences avoided by radiotherapy.
Allocation to radiotherapy halved the average annual rate of any fi rst recurrence (rate ratio [RR] 0·52, 95% CI 0·48-0·56, fi gure 1). The proportional reduction was greatest in the fi rst year (0·31, 0·26-0·37), but was still substantial during years 5-9 (0·59, 0·50-0·70; webappendix p 13). Beyond year 10 there was no evidence of any further eff ect on the fi rst recurrence rate, but information about recurrence in this period was incomplete so the number of events was small and the CI wide (fi gure 1). Radiotherapy reduced the annual breast cancer death rate by a sixth (RR 0·82, 0·75-0·90). The timing of breast cancer death diff ered from that of fi rst recurrence, with few events during the fi rst year (fi gure 1), and there were substantial numbers of breast cancer deaths after year 10.
Mortality without recurrence from non-breast-cancer causes was slightly higher in women allocated to radiotherapy than in women allocated to breast-conserving surgery only, but the excess was not signifi cant (RR 1·09, 95% CI 0·97-1·22, 2p=0·14). If the mortality rate from non-breast-cancer causes in women allocated to radiotherapy had been identical to that in women allocated to breast-conserving surgery only, then the 15-year absolute risk reduction in all-cause mortality would have been 3·2%. In fact, the 15-year absolute risk reduction in all-cause mortality was 3·0% (95% CI 0·6-5·4, 2p=0·03; fi gure 1).
Most women (n=7287) had pN0 disease. In this group, allocation to radiotherapy halved the average annual recurrence rate during the fi rst decade (RR 0·46, 95% CI 0·41-0·51), reducing the 10-year risk of any fi rst recurrence from 31·0% to 15·6%, an absolute reduction of 15•4% (95% CI 13·2-17·6, 2p<0•00001 fi gure 2). For these women, radiotherapy reduced breast cancer death by about a sixth (RR 0·83, 95% CI 0·73-0·95), and reduced the 15-year risk of breast cancer death from 20·5% to 17·2%, an absolute reduction of 3·3% (95% CI 0·8-5·8, 2p=0•005; fi gure 2).
For the 1050 women with pN+ disease, allocation to radiotherapy reduced the 1-year recurrence risk from Treatment effect 2p<0·00001 99% CI or * 95% CI 26·0% to 5·1%, which is a fi ve-fold reduction (RR 0·20, 95% CI 0·14-0·29). There was a moderate additional eff ect over the next few years but little further eff ect after year 5 (fi gure 2). When these very diff erent proportional eff ects in diff erent periods since treatment were combined, the mean annual recurrence rate during the whole of the fi rst decade was halved in pN+ disease (RR 0·50, 95% CI 0·41-0·61). Although the proportional reductions in the mean annual recurrence rate were similar in pN0 and pN+ disease, the absolute 10-year recurrence reduction seemed to be somewhat larger in pN+ disease at 21·2% (95% CI 14·5-27·9, 2p<0·00001, 42·5% vs 63·7%). Radiotherapy also reduced breast cancer death in pN+ disease (RR 0·79, 95% CI 0·65-0·95, 2p=0·01), with a 15-year absolute reduction of 8·5% (95% CI 1·8-15·2; 42·8% vs 51·3%).
In both pN0 and pN+ disease, the fi rst recurrence was locoregional for a higher proportion of women allocated to breast-conserving surgery only than of women allocated to breast-conserving surgery plus radiotherapy (web appendix p 10).
Analyses of the eff ects of treatment in various subgroups of women with pN0 disease are much more likely to identify diff erences reliably if they are based on recurrence than on mortality, because the signifi cance level of the eff ect of radiotherapy is much more extreme for recurrence than for mortality (2p<0·00001 for recurrence [ 
Table 2: Eff ect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any (locoregional or distant) fi rst recurrence in women with pathologically node-negative disease (n=7287), subdivided by patient and trial characteristics
In a series of analyses which focus fi rst on proportional and then on absolute reductions in recurrence, women were subdivided into diff erent groups to ascertain whether some groups benefi t more than others from radiotherapy. In the fi rst analysis, the proportional eff ect of radiotherapy on the rate of any fi rst recurrence in pN0 disease during the fi rst 10 years was estimated for each of several factors considered separately (fi gure 3). In most subgroups, radiotherapy roughly halved the annual recurrence rate (except that among women who had been Halving a big risk produces a bigger absolute benefi t than halving a small risk. In women with pN0 disease, the annual recurrence rate without radiotherapy was strongly correlated with age (inversely), tumour grade, tumour size, ER status (especially when tamoxifen was used in ER-positive disease), and extent of surgery (inversely). The absolute recurrence reduction produced by radiotherapy also depended strongly on these factors (table 2) . In the second analysis, the way in which the absolute reduction in 10-year recurrence risk produced by radiotherapy depended on all the potential explanatory factors listed in table 2 considered together was modelled.
The modelling was carried out by considering information both for women allocated to radiotherapy and for those allocated to no radiotherapy (webappendix pp 20-25 shows methodological details). The absolute recurrence reduction produced by radiotherapy and the absolute recurrence risk remaining even with radiotherapy varied signifi cantly with age, tumour grade, ER status, and tamoxifen use, even after adjustment for all other factors (table 2). Tumour size was independently predictive of absolute recurrence risk although not of the absolute risk reduction.
When the original trials with lumpectomy (category A) and the later trials with lumpectomy in low-risk women (category C) were compared, there was a substantial diff erence in the absolute recurrence risk without radiotherapy and in the absolute reduction in this risk produced by radiotherapy, but these diff erences were largely accounted for by the other recorded factors (table 2; webappendix pp [15] [16] [17] 19) .
Surgery that is more extensive than lumpectomy (as in the category B trials) reduced the absolute recurrence risk without radiotherapy and reduced the absolute reduction in this risk produced by radiotherapy. However, because the category B trials did not give tamoxifen, this eff ect of the extent of surgery on the absolute eff ect of radiotherapy was apparent only after adjustment for tamoxifen use (and the other recorded factors), but not before (table 2; webappendix p 18).
The characteristics that were independently predictive of the absolute risk of recurrence, or of the absolute risk reduction with radiotherapy, were included in a model to show how 10-year recurrence risks with and without radiotherapy depended in these trials on age, grade, ER status, tamoxifen (which was given much more often in the recent category C trials of low-risk patients than in the original category A trials), and extent of surgery. Figure 4 shows estimates based on this model. Within each section of the fi gure, younger women and those with high-grade tumours had substantially larger absolute recurrence risks without radiotherapy and substantially larger absolute risk reductions with radiotherapy than did older women and those with low-grade tumours (fi gure 4). Among women given lumpectomy but not radiotherapy, for a specifi c age and grade, the highest risks and largest absolute reductions with radiotherapy were for women with ER-positive disease not given tamoxifen; however, even with tamoxifen the additional eff ects of radiotherapy were substantial for women with high-grade tumours and younger women with intermediate-grade tumours (fi gure 4).
Each woman with pN0 disease was assigned a predicted absolute reduction in 10-year recurrence risk from radiotherapy on the basis of her individual characteristics, the characteristics of the trial that she was in, and the modelbased estimates in fi gure 4. The absolute reduc tion in 10-year recurrence risk was large (≥20%) for 1924 women (56% of women in trial category A, 16% of trial category B, and 9% of trial category C), intermediate (10-19%) for 3763 women (32%, 74%, and 53% of trial categories A, B, and C respectively), and lower (<10%) for 1600 women (12%, 10%, and 38% of trial categories A, B, and C respectively). For these three groups (pN0-lower, pN0-intermediate, and pN0-large), the observed 10-year recurrence risks with and without radiotherapy, calculated directly from data for individual women, were 26•0% versus 50•3% (absolute reduction of 24•3%, 95% CI 19•6-29•0), 12•4% versus 24•8% (absolute reduction of 12•4%, 9•7-15•1), and 12•0% versus 18•9% (absolute reduction of 6•9%, 2•2-11•6), respectively. The corres ponding absolute reductions in 15-year risk of breast cancer death in the three groups were 7·8% (95% CI 3·1-12·5), 1·1% (-2·0 to 4·2), and 0·1% (-7·5 to 7·7), respectively (trend in absolute mortality reduction: 2p=0·03; fi gure 5, webappendix pp 35-37). For all three groups, the fi rst recurrence was locoregional for a much larger proportion of women allocated to breast-conserving surgery only than for those allocated to breast-conserving surgery plus radiotherapy (webappendix pp 38-39). Because only 1050 women had pN+ disease in these trials, the relevance of prognostic factors and other characteristics could not be explored reliably in this group (webappendix pp 40-44).
On average, in all the women in these trials, about one breast cancer death was avoided by year 15 for every four recurrences avoided by year 10 (fi gure 1). For pN+ disease and for pN0 disease with large predicted absolute recurrence benefi t the observed ratio was slightly larger, whereas for pN0 disease with intermediate or lower predicted absolute benefi t it was somewhat smaller (fi gure 5). However, the departure from linearity was not statistically signifi cant (2p=0·11).
Discussion
The overall fi ndings from these trials show that radiotherapy after breast-conserving surgery not only substantially reduces the risk of recurrence but also moderately reduces the risk of death from breast cancer. These results suggest that killing microscopic tumour foci in the conserved breast with radiotherapy reduces the potential for both local recurrence and distant metastasis. Both proportional and absolute reductions in the annual recurrence rate are largest in the fi rst year but the recurrence rate continues to be somewhat lower throughout the fi rst decade, whereas the reduction in breast cancer death rate becomes defi nite only after the fi rst few years and appears to continue into the second decade. Non-breast-cancer mortality and the incidence of contralateral and other second cancers in these and other trials of radiotherapy in early breast cancer will be reported elsewhere, but there appeared to be little adverse eff ect on 15-year mortality from the aggregate of all causes other than breast cancer, so 15-year all-cause mortality was reduced by almost as much as would be expected from the reduction in breast cancer mortality.
Previous analyses had shown that in pN0 disease young age, large tumour size, and high grade were each strongly predictive of the risk of locoregional recurrence and of the absolute reduction in that risk with radiotherapy. 5 This report combines the predictive value of these and other factors, such as wider tamoxifen use in recent trials. Taken together, they account for the fact that the absolute recurrence reduction with radiotherapy is lower in the more recent postlumpectomy trials (ie, category C trials) than in the original postlumpectomy trials (ie, category A trials, table 2). However, even for women with pN0 disease in the recent low-risk trials the predicted absolute 10-year recurrence reduction with radio therapy exceeded 10% in most women and exceeded 20% in some women.
Almost a quarter of women with pN0 disease were in trials in which sector resection or quadrantectomy, rather than lumpectomy, was undertaken and tamoxifen was not trial policy for pN0 disease in any of these trials. Recurrence rates were, however, lower than those for women with similar characteristics in trials in which lumpectomy was performed (fi gure 4). This diff erence accords with the fi ndings of the one randomised trial of quadrantectomy versus lumpectomy, both with radiotherapy, in 700 women, two-thirds of whom were node negative. 25 Most of the trials of radiotherapy after lumpectomy required negative surgical margins for invasive cancer (although not for ductal carcinoma in situ). However, pathological techniques have become more sensitive since the women entered these trials, and some would probably have been positive with modern techniques. Therefore, whether the lower recurrence rates recorded in trials of radiotherapy in women given sector resection or quadrantectomy are simply the result of a reduction in the proportion of women with positive margins, or whether there is further benefi t to be derived from more extensive surgery, is unknown.
The classifi cation of pN0 disease into three groups with large, intermediate, and lower predicted absolute recurrence benefi t from radiotherapy was derived from the recurrence data in these trials. The classifi cation cannot be validated externally and so should not be overinterpreted. Nevertheless, the size of the diff erence in the absolute recurrence reduction between the three groups is striking. Furthermore, the 15-year reduction in risk of breast cancer death was about as big in pN0 disease with large predicted absolute recurrence benefi t as it was in pN+ disease, whereas in pN0 disease with intermediate or lower predicted recurrence benefi t the mortality reduction was smaller and neither diff ered signifi cantly from zero. Therefore the number of breast cancer deaths avoided per recurrence avoided might be more than one in four in pN+ disease and in pN0 disease with large predicted absolute recurrence benefi t, and less than one in four for women with intermediate or lower predicted absolute benefi t (fi gure 5). However, the present data do not depart signifi cantly from the one-infour relationship.
The main analyses presented are of fi rst recurrence of any type rather than, as previously, locoregional recurrence as a fi rst event. This diff erence is partly because it is now clear that radiotherapy after breastconserving surgery reduces breast cancer death, so it must also reduce distant recurrence. It is also because women with higher risk of locoregional recurrence have higher risk of distant recurrence (ie, the probabilities of locoregional and of distant recurrence are not statistically independent), so valid estimates of the separate eff ects of radiotherapy on local and distant recurrence cannot be obtained. 26, 27 These issues are more important at 10 years than at 5 years (as presented previously), because more distant recurrences occur by 10 years than by 5 years. The fact that the proportion of fi rst recurrences that were locoregional was much lower in irradiated women than in controls does, however, suggest that the main eff ect of radiotherapy was to reduce locoregional recurrence, whereas the reduction of the breast cancer death rate by a sixth suggests that the distant recurrence rate was reduced by at least as much. No analyses have been undertaken of recurrences after the fi rst, because they are aff ected by treatment policies for the fi rst recurrence, and many trials did not record further recurrences.
Screening, surgery, pathology, radiotherapy, and systemic therapy 28, 29 have all changed substantially since most of the women entered these trials, so the absolute recurrence reduction with radiotherapy in future patients might diff er greatly from that recorded in these trials. Moreover, information about additional risk factors will often be available (eg, HER2, gene expression profi le, margin status) and a radiotherapy boost may be given. 30, 31 Nevertheless, the fi nding that radiotherapy roughly halved the recurrence rate after breast-conserving surgery in a wide range of patients with very diff erent absolute risks (fi gure 3) suggests that it might also roughly halve the recurrence rate in future patients given breastconserving surgery but who are not comparable with the women included in the trials analysed here. If so, then in these future patients, a reasonable way to predict the absolute recurrence benefi t of radiotherapy would be to construct contemporary estimates of the absolute risk of fi rst recurrence of any type and to assume that radiotherapy will approximately halve it.
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